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prices for medicines awarded an ASMR (additional medical benefit) rating of I to 
III, and those with an ASMR IV in relation to medicines recently rated at ASMR 
levels I to III, will not be lower than the lowest price in the 4 main reference EU 
markets, for 5 years. Our aim is to assess whether this price guarantee has been 
respected for price cuts published in the Official Journal between January 2013 and 
July 2015. Methods: Based on MAPI® database collecting price cuts and ASMR 
ratings, we screened medicines granted relevant ASMRs, and identify those affected 
by at least one price cut within the 5-years period following their admission to 
reimbursement. Results: As of June 11, 2015, amongst medicines with price cuts 
despite an ASMR I to III or IV granted in less than 5 years, 12 had been admitted to 
reimbursement for more than 5 years, recent ASMR being granted to extended indi-
cations. Within the 5 years following their reimbursement, price cuts were observed 
for only 4 medicines granted an ASMR III (abiraterone, boceprevir, telaprevir and 
vemurafenib) and 4 granted an ASMR IV (apixaban, denosumab, solifenacin and 
ulipristal acetate). ConClusions: Overall, the 5-years price stability for innova-
tive medicines fulfilling the criteria set by the agreement is verified, price cuts 
concerning mainly mature products. Price cuts for qualified medicines within the 
first 5 years may be due to changes in prices in reference countries, budget impact 
concerns or other reasons kept confidential.
PHP301
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objeCtives: Since October 2013, companies are requested to submit a cost-effec-
tiveness analysis when applying to reimbursement for pharmaceuticals or medical 
devices and claiming from a major to a moderate additional medical benefit versus 
comparators (ASMR/ASA/ASR I-III). Efficiency appraisals are published after comple-
tion of the procedure and prices made public. They include critics of the methodol-
ogy classified as minor, important and/or major limitations. Our aim is to present an 
analysis of these appraisals. Methods: Results of appraisals in terms of ICERs and 
limitations will be presented along with the medical assessment (target population, 
therapeutic area, SMR/ASMR) and the annual treatment price. Limitations will also 
be detailed. Results: As May 2015, a cost/effectiveness analysis was required for 
28 pharmaceuticals and 1 medical device. Five (alemtuzumab, dolutegravir, rioc-
iguat, sofosbuvir, trastuzumab emtasine) have been published. They concern dif-
ferent therapeutic areas (pneumology, infectiology, oncology, neurology) and target 
populations (from 1,000 patients in CTEPH to 130,000 in hepatitis C). ASMR granted 
vary from IV to II, with one medicine granted a negative SMR. Efficiency has been 
assessed either for the full indication of the market authorization or only a restricted 
one. The ICERs varied from less than € 20,000 to almost € 200,000/QALY at companies 
requested prices, with treatment cost varying from € 6,000 to € 60,000. In case of 
major limitations, efficiency is not assessed, with negative impact on the following 
price negotiations. In case of important limitations, results have to be cautiously 
interpreted. ConClusions: These 5 published assessments provide key learnings 
about the French HTA body’s expectations. More evidence impact on the price nego-
tiation is expected with upcoming assessments to be published and through ICERs 
calculation with published prices.
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objeCtives: To asses and obtain data on the proper use of drugs and present irra-
tional drug use pattern by medical practitioners that weather the patients receive 
the medicines, weather these are appropriate for their clinical needs, in proper doses, 
for appropriate periods of time, weather cost effective and were dispensed prop-
erly. Methods: This study was designed to asses’ irrational drug use pattern which 
is a great concern of the entire world and WHO in general and in our country in 
particular. For this study we used the WHO indicators utilizing the services of trainee 
Pharmacists in two major city Hospitals. This study was conducted from April, 15th 
2014 to May, 14th 2014. Data was collected using patient’s prescriptions and direct 
patient communication using a structured check list for the prescribing indicators 
including number of drugs per prescription, number of antibiotics, number of injec-
tions, number of steroids and number of food supplements. The patient care data 
was directly interpreted and analyzed over the dispensing counters. Results: The 
results showed that in both hospitals (860 prescriptions), the average number of drugs 
per prescription were 5, the patients were prescribed antibiotics at least two antibiot-
ics per prescription (40%), (The antibiotics were mainly Amoxicillin, Co-amoxiclav, 
Ciprofloxacin, Norfloxacin and Flouroquinolones. It was also observed that in some 
cases the antibiotics of choice were not recommended). The percentage of injec-
tions, steroids and food supplements were 20% each. The percentage of proper doses, 
proper timing, cost effectiveness and proper dispensing was 70%, 60%, 20% and 20% 
respectively. This irrational prescribing pattern/habit of the medical practitioners was 
observed in both the hospitals. ConClusions: This study indicates that this type of 
irrational practice is the reflection of state and regulatory affairs in the country which 
need strict regulations and strategies for drug prescriptions and dispensing including 
the utilization of services of more Pharmacists.
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objeCtives: To discuss about the LP 7169/2014, the new Law Project that wants to 
regulate the conflicts’ mediation in Brazil, and to describe the successful experi-
ence of the conflicts’ mediation between health plans and consumers promoted 
guidance on how clinicians should approach a conversation with patients about 
economic value. ConClusions: Our review demonstrates that efforts to incor-
porate economic data to support clinical decision-making are still in its early 
stages. A number of societies consider basic cost or burden elements as part of 
topic selection or recommendation formulation. None of the reviewed societies 
have systemically incorporated economic assessment in a manner that would 
enable the physician and the patient to jointly make an informed decision based 
on value. Researchers have a clear role to play in helping guideline developers 
incorporate the patient perspective in discussions of cost/cost-effectiveness, and 
helping physicians develop tools to communicate value.
HEAltH cArE usE & Policy studiEs – Quality of care
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objeCtives: Health information technologies represent a valuable tool to pro-
mote a better use of medicines and optimize health expenditure. The purpose of 
this study is to assess advantages provided by the use of technological supports 
to detect medication errors (MEs) in a community setting. Methods: In 2011, 
the Local Health Unit (LHU) Caserta established an innovative web platform, the 
Saniarp PHT. This platform allows tracking of drug prescriptions included in the 
Hospital-Territory Formulary (PHT), and puts in network medical specialists working 
in Prescribing Centers of regional relevance, community pharmacies and General 
Practioners (GPs). Through this platform, LHU can perform real time checks on 
prescription, distribution and inventory of PHT drugs. A multidisciplinary team 
checks each prescription that LHU received and confirm or not the distribution. A 
retrospective cross-sectional analysis was performed (Sept 2013-Sept 2014) to evalu-
ate frequencies and types of ME occurred during the observation period. MEs were 
then classified according to MedDRA Preferred Term Groups on the basis of Draft 
World Health Organization (WHO) ME Classification. Results: During the observa-
tion period, 1233 MEs were detected. The most frequent MEs were “Circumstance 
or information capable of leading to medication error” (n= 761, 61,7%), followed by 
“Intercepted drug prescribing error” (n= 194, 15,7%). The main anatomical groups 
most frequently associated with MEs were nervous system agents (48%), antineo-
plastic and immunomodulating agents (16%) and systemic anti-infectives agents 
(11,5%). ConClusions: Preventing MEs is important not only for patients’ safety, 
but also to optimize financial resources. Our data show that technological sup-
ports give consistent advantages in the MEs’ detection. Moreover, these tools are 
useless if not associated with a professional figure like pharmacist, or, even better, 
a multidisciplinary team.
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objeCtives: Japan Council for Quality Health Care (JCQHC) is the only organiza-
tion to accredit hospitals according to its evaluation standard in Japan. This study 
aims to explore the association between accreditation scores on health care quality, 
patient safety and medical ethics, and the hospital characteristics. Methods: As of 
March 2nd, 2012, 2,437 hospitals were accredited by JCQHC. In those hospitals, 848 
hospitals have been participating in the public disclosure. Out of 848, we extracted 
454 hospitals accredited according to version 5.0 JCQHC evaluation standards from 
the JCQHC database and we evaluated their scoring about 2nd area of “patients’ 
rights and systems for securing patient safety”. The accreditation surveyors rated 
each item from 1 (poor) to 5 (excellent). Results: The 454 hospitals included 41 
university hospitals (UHs) and 411 general hospitals (GHs). The mean scores for 
411 GHs and 41 UHs of 2.1.2 “Policy on professional ethics is clearly indicated” 
were 3.46±0.518 and 3.41±0.499 (p= 0.593). And those of 2.1.3 “Policy on clinical eth-
ics is clearly indicated” were also 3.22±0.478 and 3.37±0.488 (p= 0.070). There were 
statistically no significance between GHs and UHs. Similarly, the mean scores for 
411 GHs and 41 UHs of 2.1.4 “Policy on clinical trial studies is clearly indicated” 
were 3.87±0.368 and 4.00±0.224 (p= 0.027). And, those of 2.1.5 “Policy on clinical 
researches is clearly indicated” were 3.75±0.473 and 3.93±0.264 (p= 0.018). There were 
statistically significances between two hospital groups. Furthermore, there were 
statistically significances between the items of ethics and research respectively 
(p< 0.001). Hence, the scores of items of clinical ethics have to be patient-centered 
were lower, but those of items regarding researches and trials. ConClusions: 
These findings led to the conclusion that health care professional at university 
hospitals might lack a sense of ethics and be more interested in clinical researches 
than general hospitals.
HEAltH cArE usE & Policy studiEs – regulation of Health care sector
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tHE 5-yEArs EuroPEAn PricE stABility AWArdEd to innovAtivE 
mEdicinEs: is it vErifiEd in PrActicE?
Mézerette B1, Chevalier J2, Delaitre C2, Chicoye A2
1MAPI GROUP, Paris, France, 2MAPI Group, Paris, France
objeCtives: Admission to reimbursement in France for drugs is implemented 
conventionally through framework agreements between the industrial association 
(LEEM) and the Economic Committee (CEPS) encompassing price setting, expendi-
ture regulation and industrial policy. According to the agreement currently enforced, 
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assess whether the drug costs stated in BIA matches to real costs. Methods: Twelve 
HID obtained CED in 2013. The drug costs were identified in BIA of eleven HID. Real 
costs of General Health Insurance Company (VZP) were found out for each HID in 
the first year of therapy. As VZP holds 60% of the health insurance market, the data 
were extrapolated to the whole population. The differences between estimated and 
real drug costs were analysed and a correlation between this differences and drug 
characteristics justifying their HID status were investigated. Results: The estimated 
costs were exceeded in five cases (overrun between 31-332%). In six cases real costs 
did not achieve the estimation (12-91% of estimated costs). Concerning effectiveness 
and safety characteristics of investigated drugs, within seven drugs granted as HID 
because of absence of an alternative drug, four exceeded the estimation. One of two 
drugs granted as HID because of adverse effects reduction compared with current 
treatment exceeded the estimation. Remaining two drugs did not achieve the estima-
tion, one was granted HID because of mortality reduction, another because of higher 
effectiveness compared with current treatment. ConClusions: However HID costs 
estimated in BIA are submitted in order to predict costs of public health insurance, 
the analysis did not prove their validity and contribution to a reasonable decision 
making. Despite the fact that BIA is a mandatory requirement and it is cost and time 
consuming, its role is formal only and its premises have neither practical impact nor 
they are subject of further review.
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rEviEW of PoliciEs And PErsPEctivEs on rEAl-World dAtA for drug 
dEvEloPmEnt And AssEssmEnt (imi-gEtrEAl dElivErABlE)
Makady A1, Goettsch W2
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2National Healthcare Institute 
(ZiN), Diemen, The Netherlands
objeCtives: To conduct a review of different stakeholders’ policies and perspectives 
on using Real-World Data (RWD) for early drug development and clinical effective-
ness assessment in order to shed light on the possibilities for the incorporation 
of RWD and Real-World Evidence (RWE) in both aspects. Methods: A qualitative 
methodology was selected that combines semi-structured interviews with a litera-
ture review. 19 stakeholders from 8 different stakeholder groups were interviewed. 
Meanwhile, a review of academic and grey literature was performed. Transcripts of 
interviews and data from review articles were subjected to coding analysis. Analysis 
focused on: definitions for RWD provided, current policies on RWD, context (actual 
& perceived) for RWD use, advantages and disadvantages of RWD, practical obsta-
cles to using RWD, and political and procedural implications for RWD incorpo-
ration. Results: Consensus regarding the definition of RWD and types of RWD 
was lacking among stakeholders. A current gap in policies addressing RWD also 
exists. Despite this, RWD is currently used for reimbursement, regulatory and drug 
development processes. RWD has high external validity & generalisability and can 
provide valuable data on long-term outcomes. Yet biases in data, poor data quality 
(completeness, comprehensiveness) and lack of standardisation entice scepticism 
for its use. Ambiguity still remains on governance of RWD/RWE as well as a cultural 
barrier among stakeholders against the use of RWD/RWE. ConClusions: Increased 
stakeholder collaboration is needed to harmonise definitions and evidence needs of 
RWD, reach consensus on the relevance of RWD for addressing specific questions, 
and to standardise RWD data collection and analysis methods.
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EfficAcy-EffEctivEnEss-gAP – ExtEnt, cAusEs And imPlicAtions
Amler N1, Zottmann D1, Bierbaum M2, Schöffski O1
1Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany, 2Hochschule Aalen - 
Technik und Wirtschaft, Aalen, Germany
objeCtives: The term efficacy-effectiveness-gap refers to the difference between 
the outcomes received within randomized controlled trials and those observed 
in real-word clinical practice. The phenomenon is often described in literature 
whereas papers generally remain unassertive or unspecific. The objective of our 
paper is to give a summary of the literature regarding extent, causes and implica-
tions of the gap. Methods: A systematic review was undertaken. We searched 
PubMed, the Cochrane Library and Scopus for relevant articles. Papers assessing 
extent, causes and/or implications were included. Only full-papers in English or 
German language were eligible. Scanning reference lists, internet search and tar-
geted contact with experts complemented our search. Two authors independently 
reviewed titles, assessed articles’ eligibility for inclusion and extracted relevant 
data. Results: In total 650 studies were identified. 27 of them met the inclusion 
criteria. We found that causes were most often analyzed in literature. The causes 
most often mentioned include patient-related causes such as lack of adherence, 
but also health-system related, service-provider-related as well as disease- or drug-
related causes. 18 studies derived implications. Implications found predominantly 
focus on possibilities on how to bridge the gap. Only 5 articles address the extent 
of the gap whereof not a single one actually tried to quantify it. Instead, statements 
remain unassertive (“quite large”, “huge”, etc.) and results diverge regarding size as 
well as direction. ConClusions: While the causes of the gap seem to be relatively 
well understood, there is a lack of studies trying to analyze the actual extent of the 
gap. Authors encourage further research especially on approaches to quantify the 
extent of the gap.
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intRoduCtion: In Egypt, health insurance organization (HIO) was established 
since 1964 as the governmental health insurer for public servants. Since then, it 
has significantly grown both in coverage and services as it currently covers 58% of 
by The Federal Regulatory Agency for Private Health Insurance and Plans (ANS) in 
supplementary health sector. Methods: A comparative analysis between the LP 
7169/2014 and the NR 343/2013 (normative resolution that defines mediation rules 
in ANS currently) was made focusing on their similarities and differences. Results: 
According to the LP, mediation is an alternative way to solve controversies in pub-
lic administration. In supplementary health sector, the only way to have conflicts 
solved by ANS is through mediation. It’s not an option, but the first step to every 
patient complaint about its health plan. Another difference is about the mediation 
closing. The LP provides the autonomy of the parties while in ANS, the mediation 
is just closed when there’s no irregularities or when the problem is really solved 
by the health plan. The comparison allowed the identification of some common 
principles like equality, good faith, the search for consensus and neutrality of the 
mediator. ConClusions: The conflicts’ mediation in supplementary health sector 
is a successful experience developed by the ANS. It has some rules defined by the 
NR. The LP brings some other rules to the mediation of conflicts in the public admin-
istration. So, it’s possible to note that the mediation carried out by ANS nowadays 
is not fully suited to the Law Project. Maybe, the deeper knowledge of successful 
experiences in other countries, where the tool is more widespread, could guide the 
discussion about the improvement of the current LP and also point the best way to 
adapt the existing experiences in Brazil to the new legal provision.
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usAgE ProfilE of tHE AvAilABlE cHAnnEls for comPlAints
Silva FH, Fonseca LM
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objeCtives: To identify the most used way to make complaints about health plans 
to The Federal Regulatory Agency for Private Health Insurance and Plans (ANS) in 
Brazil. Methods: A retrospective analysis of data was done to identify the most 
used channel of the three currently available: the personal, the call center and the 
electronic. Two different periods were considered to the study: the second semester 
of 2013 (the last one that still used an institutional email to the electronic com-
plaints) and the second semester of 2014 (after the creation of a specific form for 
complaints available on ANS website). Results: According to the data, the way 
most consumers choose to make a complaint is the call center (68,5% -2013 and 
71,7%-2014). The second one is the electronic way. Comparing the two periods of 
the study it’s possible to note a decrease of 5% in the use of electronic complaints 
after the form implementation (26% to 21%). The less used way is the personal one 
(6, 7% -2013 5,4%-2014). The study doesn’t point a clear relationship between the 
themes of the complaints and the kind of service used. ConClusions: The study 
showed the call center is the primary service used. The personal service is less 
used then the others, probably because it’s offered only in the biggest Brazilian 
cities. The implementation of the electronic form, through which the consumer 
can register and track their complaints, didn’t increase the use of this channel. It’s 
possible that form design, with required fields and limited number of characters, is 
acting like a complicating factor. As is known, the excessive work of the call center 
can compromise its quality and efficiency. So, it would be interesting to verify the 
key points to improve the electronic form to spread its use aiming to reduce costs 
through a future staff downsizing.
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objeCtives: In 2012 the Hungarian intensive care units system was restruc-
tured. The multidiscipline intensive care units were separated from the postop-
erative intensive units and the one specialty intensive units. The effect of it was 
analyzed. Methods: Data were got from the National Health Insurance Fund 
Administration of the intensive care units for 10 years. There were investigated 
the organizational and the patient care related data. Results: In 2012 the number 
of the multidiscipline intensive care units decreased 20% and the number of beds 
decreased 10%. Due to reorganization both the CMI and days of mechanical ventila-
tion increased significantly in the multidiscipline intensive care units. In 2000 the 
12% of the patients were discharged from the intensive care units to home, but by 
2014 this rate decreased to 3%. It showed the use of the intensive care units were 
partially unnecessary before the reorganization. If we take the optimal bed-usage 
for the intensive care units to be 85%, in the new situation the actually available 
reimbursement approached to the theoretical value. The average bed-usage was 
55% in the both period, but the statistical variance between the separated intensive 
care units decreased in the last years. ConClusions: The results shows that the 
reorganization was effective. Level of the intensive care have got higher, the use of 
the beds and the reimbursement increased. It is suggested to do similar reorganiza-
tions in the other specialties.
HEAltH cArE usE & Policy studiEs – risk sharing/Performance-Based  
Agreements
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tHE rElAtion BEtWEEn rEAl costs of drugs tEmPorArily rEimBursEd 
in modE of covErAgE WitH EvidEncE dEvEloPmEnt And BudgEt imPAct 
AnAlysis suBmittEd As A mAndAtory rEQuirEmEnt of tHE APPlicAtion
Zizalova J, Rrahmaniova D, Svorcikova J, Vrubel F
Ambruz & Dark Deloitte Legal, Prague 8, Czech Republic
objeCtives: The coverage with evidence development (CED) is a mode of reimburse-
ment intended for highly innovative drugs (HID) in the P&R system in the Czech 
Republic. Cost-effectiveness analysis and budget impact analysis (BIA) are mandatory 
requirements for setting the reimbursement. The objective of the present study was to 
